Autopsy report · NCT04702789

Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.

“For interests of sponsor.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 2 years 1 month before it stopped.
• 28 participants enrolled.
• Results were posted on the registry 2 years 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Laboratorios Sophia S.A de C.V.

Sponsor type

Industry

Conditions

Glaucoma, Open-Angle; Ocular Hypertension

Interventions

Dorzolamide-timolol-brimonidine and latanoprost; Dorzolamide-timolol and latanoprost

Participants

28

Sites

1

Countries

Mexico

Trials that died the same way

• Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
  “Sponsor Decision.” (78% match in meaning)
• A Study of PY314 in Subjects With Advanced Solid Tumors
  “Sponsor business decision.” (77% match in meaning)
• Cymbalta for Fibromyalgia Pain - Predictive Value of Small Fiber Changed
  “Sponsor related” (77% match in meaning)
• An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options
  “Sponsor request” (76% match in meaning)
• BST-DERMON Versus Standard of Care in the Treatment of Diabetic Foot Ulcers
  “Due to Sponsor's financial reasons” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.